BioLine Rx (FRA:YP2) Interest Expense: €-0.93 Mil (TTM As of Mar. 2026)


FRA:YP2 BioLine Rx Ltd FRA:YP2
21 GF Score
Price €2.52
! 5 Warning Signs
View Full Analysis

What is BioLine Rx Interest Expense?

BioLine Rx FRA:YP2 -0.79% 21 Interest Expense is €-0.93 Mil as of Mar. 2026. GuruFocus rates FRA:YP2 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BioLine Rx's interest expense for the three months ended in Mar. 2026 was € -0.22 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.93 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BioLine Rx's Operating Income for the three months ended in Mar. 2026 was € -2.60 Mil. BioLine Rx's Interest Expense for the three months ended in Mar. 2026 was € -0.22 Mil. BioLine Rx did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioLine Rx  (FRA:YP2) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioLine Rx's Interest Expense for the three months ended in Mar. 2026 was €-0.22 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-2.60 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €3.75 Mil.

BioLine Rx's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

BioLine Rx did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

BioLine Rx Interest Expense Historical Data

* Premium members only.

The historical data trend for BioLine Rx's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLine Rx Interest Expense Chart

BioLine Rx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.87 -1.69 -1.97 -8.67 -1.07

BioLine Rx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.39 -0.24 -0.26 -0.21 -0.22
FRA:YP2
21GF Score
BioLine Rx Ltd FRA:YP2
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLine Rx Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.93 Mil mean?
BioLine Rx (FRA:YP2) has a Interest Expense of €-0.93 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on BioLine Rx and its competitors.
Is BioLine Rx's Interest Expense too high?
BioLine Rx's current Interest Expense is €-0.93 Mil. Overall, BioLine Rx has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's Interest Expense compare to VRTX and REGN?
BioLine Rx's Interest Expense of €-0.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on BioLine Rx and its competitors. BioLine Rx's current Interest Expense is €-0.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (FRA:YP2) has a current Interest Expense of €-0.93 Mil. The current Interest Expense is €-0.93 Mil. BioLine Rx's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For BioLine Rx (FRA:YP2), the current Interest Expense is €-0.93 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLine Rx Business Description

Other Exchanges BLRX:USABLRX:Israel
Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
21GF Score

Get the complete analysis for FRA:YP2

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.52
Price